Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection

References

• DubberkeERCarlingPCarricoRStrategies to prevent Clostridium difficile infections in acute care hospitals: 2014 updateInfect Control Hosp Epidemiol201435Suppl 2S4865
   PubMed Web of Science ®Google Scholar
• CohenSHGerdingDNJohnsonSClinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)Infect Control Hosp Epidemiol201031543145520307191
   PubMed Web of Science ®Google Scholar
• LessaFCMuYBambergWMBurden of Clostridium difficile infection in the United StatesN Engl J Med2015372982583425714160
   PubMed Web of Science ®Google Scholar
• DubberkeEROlsenMABurden of Clostridium difficile on the healthcare systemClin Infect Dis201255Suppl 2S88S9222752870
   PubMed Web of Science ®Google Scholar
• DesaiKGuptaSBDubberkeERPrabhuVSBrowneCMastTCEpidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approachBMC Infect Dis20161630327316794
   PubMed Web of Science ®Google Scholar
• Sheitoyan-PesantCAbou ChakraCNPepinJMarcil-HeguyANaultVValiquetteLClinical and healthcare burden of multiple recurrences of Clostridium difficile InfectionClin Infect Dis201662557458026582748
   PubMed Web of Science ®Google Scholar
• AwadMMJohanesenPACarterGPRoseELyrasDClostridium difficile virulence factors: insights into an anaerobic spore-forming pathogenGut Microbes20145557959325483328
   PubMed Web of Science ®Google Scholar
• Di BellaSAscenziPSiarakasSPetrosilloNdi MasiAClostridium difficile toxins A and B: insights into pathogenic properties and extraintestinal effectsToxins (Basel)201685
   PubMed Web of Science ®Google Scholar
• TaylorCPTummalaSMolrineDOpen-Label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin AVaccine20082627–283404340918502001
   PubMed Web of Science ®Google Scholar
• LyrasDO’ConnorJRHowarthPMToxin B is essential for virulence of Clostridium difficileNature200945872421176117919252482
   PubMed Web of Science ®Google Scholar
• CarterGPRoodJILyrasDThe role of toxin A and toxin B in Clostridium difficile-associated disease: past and present perspectivesGut Microbes201011586420664812
   PubMed Web of Science ®Google Scholar
• McDonaldLCKillgoreGEThompsonAAn epidemic, toxin gene-variant strain of Clostridium difficileN Engl J Med2005353232433244116322603
   PubMed Web of Science ®Google Scholar
• YangZRamseyJHamzaTMechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumabInfect Immun201583282283125486992
   PubMed Web of Science ®Google Scholar
• VedantamGClarkAChuMMcQuadeRMallozziMViswanathanVKClostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host responseGut Microbes20123212113422555464
   PubMed Web of Science ®Google Scholar
• WarnPThommesPSattarADisease progression and resolution in rodent models of Clostridium difficile Infection and impact of antitoxin antibodies and vancomycinAntimicrob Agents Chemother201660116471648227527088
   PubMed Web of Science ®Google Scholar
• HumphreysDPWilcoxMHAntibodies for treatment of Clostridium difficile infectionClin Vaccine Immunol201421791392324789799
   PubMedGoogle Scholar
• GuptaSBMehtaVDubberkeERAntibodies to toxin B are protective against Clostridium difficile infection recurrenceClin Infect Dis201663673073427365387
   PubMed Web of Science ®Google Scholar
• ZhangZChenXHernandezLDToxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infectionInfect Immun201583140541625385797
   PubMed Web of Science ®Google Scholar
• KoonHWShihDQHingTCHuman monoclonal antibodies against Clostridium difficile toxins A and B inhibit inflammatory and histologic responses to the toxins in human colon and peripheral blood monocytesAntimicrob Agents Chemother20135773214322323629713
   PubMed Web of Science ®Google Scholar
• JohnsonSLouieTJGerdingDNVancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trialsClin Infect Dis201459334535424799326
   PubMed Web of Science ®Google Scholar
• DebastSBBauerMPKuijperEJEuropean Society of Clinical Microbiology and Infectious DiseasesEuropean Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infectionClin Microbiol Infect201420Suppl 2126
   PubMed Web of Science ®Google Scholar
• CornelyOANathwaniDIvanescuCOdufowora-SitaORetsaPOdeyemiIAClinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparisonJ Antimicrob Chemother201469112892290025074856
   PubMed Web of Science ®Google Scholar
• MartinJWilcoxMNew and emerging therapies for Clostridium difficile infectionCurr Opin Infect Dis201629654655427753689
   PubMed Web of Science ®Google Scholar
• KociolekLKGerdingDNBreakthroughs in the treatment and prevention of Clostridium difficile infectionNature reviews Gastroenterology & Hepatology201613315016026860266
   PubMed Web of Science ®Google Scholar
• WilcoxMHGerdingDNPoxtonIRBezlotoxumab for prevention of recurrent Clostridium difficile infectionN Engl J Med2017376430531728121498
   PubMed Web of Science ®Google Scholar
• ChapinRWLeeTMcCoyCAlonsoCDMahoneyMVBezlotoxumab: could this be the answer for Clostridium difficile recurrence?Ann Pharmacother201751980481028480750
   PubMed Web of Science ®Google Scholar
• OrthPXiaoLHernandezLDMechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallographyJ Biol Chem201428926180081802124821719
   PubMed Web of Science ®Google Scholar
• MullardAFDA approves antitoxin antibodyNature reviews Drug discovery20161512811
   Web of Science ®Google Scholar
• Zinplava (bezlotoxumab) [prescribing information]Whitehouse Station NJMerck & Co, Inc2016
   Google Scholar
• LowyIMolrineDCLeavBATreatment with monoclonal antibodies against Clostridium difficile toxinsN Engl J Med2010362319720520089970
   PubMed Web of Science ®Google Scholar
• BabcockGJBroeringTJHernandezHJHuman monoclonal antibodies directed against toxins A and B prevent Clostridium difficile- induced mortality in hamstersInfect Immun200674116339634716966409
   PubMed Web of Science ®Google Scholar
• DzunkovaMD’AuriaGXuHThe monoclonal antitoxin antibodies (actoxumab-bezlotoxumab) treatment facilitates normalization of the gut microbiota of mice with Clostridium difficile infectionFront Cell Infect Microbiol2016611927757389
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA Briefing Document Bezlotoxumab Injection. BLA 761046: bezlotoxumab injectionFDA2016 Available from: https://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycom-mittee/ucm505290.pdfAccessed December 5, 2017
   Google Scholar
• HernandezLDRacineFXiaoLBroad coverage of genetically diverse strains of Clostridium difficile by actoxumab and bezlotoxumab predicted by in vitro neutralization and epitope modelingAntimicrob Agents Chemother20155921052106025451052
   PubMed Web of Science ®Google Scholar
• GolanYDubberkeEHansonMBezlotoxumab (BZO) decreases recurrence and is associated with a reduction in 30-day Clostridium difficile infection-associated readmissions in hospitalized patients with CDIASM Microbe2016Boston Abstract 449
   Google Scholar